No benefits of minimally invasive total hip arthroplasty via Watson-Jones approach: A retrospective cohort study.


Journal

The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
ISSN: 1479-666X
Titre abrégé: Surgeon
Pays: Scotland
ID NLM: 101168329

Informations de publication

Date de publication:
Oct 2022
Historique:
received: 24 09 2020
revised: 29 06 2021
accepted: 13 07 2021
pubmed: 15 8 2021
medline: 21 9 2022
entrez: 14 8 2021
Statut: ppublish

Résumé

There is controversy about the role of minimally invasive surgery (MIS) for total hip arthroplasty (THA). The present study aimed to investigate whether a MIS approach has a positive impact on the outcome of THA via the Watson-Jones anterolateral approach. Clinical scores and radiological findings of minimally and standard invasive exposures were evaluated and compared. The present study was conducted according to the STROBE statement. Patients operated between 2017 and 2018 in two different orthopaedic institutions was performed. Patients with symptomatic coxarthrosis reducing considerably patient's quality of life were asked to participate in the present study. Patients were divided into two THA groups: MIS and standard invasive surgery (SIS). Surgical procedures were performed in by two experienced surgeons via the Watson-Jones approach. Data from 140 patients were collected (70 patients for each group) at two years follow-up. Leg length discrepancy was greater in the MIS cohort (P = 0.01). The Stiffness subscale of the WOMAC score resulted minimally increased in the SIS group (P = 0.03). The overall WOMAC score and the other subscales resulted similar between the two groups. Femoral offset, acetabular offset, cup orientation, cup inclination, VAS resulted similar between the two cohorts. Only a case of revision in the SIS group was reported. THA via the Watson-Jones approach achieves short terms excellent results. Surgery performed via a MIS approach does not provide any superior outcome compared to the SIS in terms of radiographic findings and clinical scores at two years follow-up.

Identifiants

pubmed: 34389254
pii: S1479-666X(21)00129-3
doi: 10.1016/j.surge.2021.07.004
pii:
doi:

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e241-e247

Informations de copyright

Copyright © 2021 Royal College of Surgeons of Edinburgh (Scottish charity number SC005317) and Royal College of Surgeons in Ireland. Published by Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest None.

Auteurs

Filippo Migliorini (F)

Department of Orthopaedic, Trauma, and Reconstructive Surgery, RWTH University Clinic Aachen, 52074, Aachen, Germany. Electronic address: migliorini.md@gmail.com.

Arnen Driessen (A)

Department of Orthopaedic, Trauma, and Reconstructive Surgery, RWTH University Clinic Aachen, 52074, Aachen, Germany. Electronic address: adriessen@ukaachen.de.

Jörg Eschweiler (J)

Department of Orthopaedic, Trauma, and Reconstructive Surgery, RWTH University Clinic Aachen, 52074, Aachen, Germany. Electronic address: joeschweiler@ukaachen.de.

Markus Tingart (M)

Department of Orthopaedic, Trauma, and Reconstructive Surgery, RWTH University Clinic Aachen, 52074, Aachen, Germany. Electronic address: mtingart@ukaachen.de.

Nicola Maffulli (N)

Department of Medicine, Surgery and Dentistry, University of Salerno, Via S. Allende, 84081, Baronissi, (SA), Italy; School of Pharmacy and Bioengineering, Keele University School of Medicine, Thornburrow Drive, Stoke on Trent, England, UK; Queen Mary University of London, Barts and the London School of Medicine and Dentistry, Centre for Sports and Exercise Medicine, Mile End Hospital, 275 Bancroft Road, London, E1 4DG, England, UK. Electronic address: n.maffulli@qmul.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH